Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
A perspective in the New England Journal of Medicine examines the evolution of heart failure treatment over the past 28 years, beginning with the introduction of vasodilator therapy in 1986 and culminating with LCZ696, an angiotensin-receptor and neprilysin inhibitor that reduced mortality in the PARADIGM-HF trial reported over the weekend.
Noting that mortality in the LCZ696 group was still high — at roughly 20% — the authors write that this new drug "hardly concludes the compelling story of heart-failure treatment... we hope that a timeline crafted three decades from now will reveal novel therapies and new paradigms that push our understanding of heart failure to a level unimaginable today."
At the European Society of Cardiology Congress on Sunday, PARADIGM-HF's principal investigators joined other experts to discuss how the trial's findings might change heart failure treatment. A video of that discussion is now available on NEJM.org.
Comment
LINK(S):
NEJM perspective (Free)
NEJM interactive timeline of 26 heart failure trials (Free)
PARADIGM-HF expert discussion (Free)